北京若生智能科技有限公司
Drug Database
AL

albumin (Zenalb)

✓ Approved

Kedrion · 细胞治疗 · 细胞治疗

什么是 albumin？

albumin 是一种细胞治疗，由Kedrion研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Intravenous (IV)。

药物档案

商品名Zenalb
公司Kedrion
药物类别细胞治疗
给药途径Injectable (Others), Intravenous (IV)
状态Approved
来源： ClinicalTrials.gov, Kedrion

治疗适应症

albumin 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Vascular disordersThrombosis✓ Approved

相关研究文献

PubMedFaraday discussions2026-10-27

Kinetically controlled proton removal via bio-inspired hybrid bilayer membrane functionalized electrode for ethylene glycol oxidation to generate C2 products.

Mo Xiaoyong X, Yu Zuo Hang ZH, Tse Edmund C M ECM

As a cornerstone of the circular carbon economy, the upcycling of polyethylene terephthalate (PET) relies on efficient monomer recovery and subsequent high-value transformation. While PET can be effectively broken down into ethylene glycol (EG) via scalable depolymerization techniques such as hydrolysis, alcoholysis, or pyrolysis, the subsequent electrochemical ethylene glycol oxidation reaction (EgOR) faces a significant selectivity bottleneck. This reaction is governed by complex proton-coupled electron transfer (PCET) pathways that typically favor C-C bond cleavage, resulting in low-value C1 products like formic acid and CO2. In this work, we overcome these limitations by employing a bio-inspired hybrid bilayer membrane (HBM) functionalized electrode to exert kinetic control over the proton removal rate. By precisely modulating the electrocatalytic microenvironment at the electrode interface, the HBM suppresses over-oxidation and steers the reaction toward the targeted generation of C2 products. We demonstrate the selective production of glycolic acid, a premium chemical in the cosmetics industry with a market value exceeding 25 times that of the EG feedstock. These results establish that regulating the kinetics of proton transfer via HBM technology is a transformative strategy for controlling reaction selectivity in complex oxidation pathways. This approach offers a potentially scalable, renewable-energy-powered route for upcycling plastic waste derivatives into high-value chemical outputs, providing significant translational value for sustainable resource recovery.

PMID 42937277
阅读全文 →
PubMedBiomolecules2026-10-27

Secretory Phospholipase A2-Albumin-Membrane Interactions: A Proposed Mechanism of Internal Cell and Tissue Injury in Systemic Inflammation.

Tsao Francis H C FHC, Meyer Keith C KC

Systemic inflammation in sepsis causes internal cell and tissue injury through mechanisms that remain incompletely understood. Secretory phospholipase A2 (sPLA2-IIA; hereafter, sPLA2), a potent inflammatory mediator whose circulating levels rise dramatically during sepsis, hydrolyzes membrane phospholipids in injured and dying cells, thereby releasing fatty acids and lysophospholipids that further amplify inflammation. Serum albumin-particularly a specific membrane-binding fraction (SFA)-normally acts as a cytoprotective scavenger of these lipid products, thereby maintaining membrane phospholipid homeostasis in concert with sPLA2. This perspective synthesizes nearly two decades of work demonstrating that the sPLA2-albumin interaction is a critical, underappreciated determinant of internal cell and tissue injury during systemic inflammation. As sPLA2 activity rises during sepsis, fatty acids generated from injured membranes progressively saturate albumin's binding sites, inducing structural misfolding that abolishes its cytoprotective capacity and paradoxically enhances further sPLA2-mediated membrane degradation. Serial serum samples from ICU patients with sepsis revealed a statistically significant positive correlation between sPLA2 activity and albumin membrane-binding-site saturation, modifiable by nutritional intervention. Age-related albumin misfolding and oxidative stress are identified as important amplifying factors. The sPLA2-albumin axis represents a promising target for biomarker development and therapeutic intervention in critically ill patients.

PMID 42939715
阅读全文 →
PubMedBiomolecules2026-10-27

Carbon Capture and Utilization Through Microalgae and Carbonic Anhydrases: Opportunities, Challenges and Future Directions.

Ferrara Alfonso A, Imbimbo Paola P, Acciaio Rocco R, Vivenzio Vincenzo Massimiliano VM et al.

The continuous increase in carbon dioxide (CO2) has intensified the need for sustainable technologies to mitigate greenhouse gas emissions. Carbon Capture and Utilization (CCU) represents a promising strategy to convert captured CO2 into valuable products, contributing to climate change mitigation and the circular economy. This review provides an overview of the main carbon management pathways, including Carbon Capture and Storage (CCS), Carbon Capture, Utilization and Storage (CCUS), and CCU, with a focus on biological CCU (bio-CCU) based on microalgae and carbonic anhydrases (CAs). Particular attention is given to the role of CAs as highly efficient biocatalysts that accelerate CO2 hydration, enhancing inorganic carbon availability. Recent advances in enzyme immobilization technologies and support materials are examined, highlighting their potential to improve enzyme stability, reusability, and process performance. Furthermore, the integration of immobilized CAs with microalgal cultivation systems is explored as an emerging strategy in which CAs facilitate inorganic carbon availability and delivery, potentially enhancing its photosynthetic fixation by microalgae and biomass productivity. Building on previous studies on microalgal bio-CCU and CA-assisted carbon capture, this review provides an integrated perspective on CA immobilization strategies, support materials, and their potential implementation in microalgal bio-CCU systems, highlighting how enzyme immobilization can connect enzymatic CO2 conversion with microalgal carbon fixation and contribute to sustainable CO2 valorization and environmental remediation.

PMID 42939643
阅读全文 →
PubMedMetabolites2026-10-27

Fibrinogen-to-Albumin, Platelet-to-Albumin, and Creatinine-to-Albumin Ratios in the Assessment of Preeclampsia Severity: A Retrospective Case-Control Study.

Kayaalp Hüseyin H, Tunc Şeyhmus Ş, Yılmaz Ebubekir Sıddık ES, Akgöl Sedat S

Background: Preeclampsia (PE) is a multisystem pregnancy disorder associated with endothelial dysfunction, inflammation, and coagulation abnormalities. This study evaluated the fibrinogen-to-albumin ratio (FAR), platelet-to-albumin ratio (PAR), and creatinine-to-albumin ratio (CrAR) in relation to preeclampsia severity. Methods: This single-center retrospective case-control study included 205 pregnant women: 104 healthy controls, 70 patients with non-severe PE, and 31 with severe PE. Clinical, obstetric, neonatal, and laboratory data were reviewed. Group comparisons, receiver operating characteristic (ROC) analysis, and logistic regression adjusted for maternal age, body mass index, and gestational age at sampling were performed. Results: Fibrinogen and FAR were significantly higher in severe than in non-severe PE. Fibrinogen showed an area under the curve of 0.685, with 67.7% sensitivity and 58.6% specificity at a cut-off of 5.05 g/L. FAR showed an area under the curve of 0.657, with 67.7% sensitivity and 64.3% specificity at a cut-off of 0.143. Both fibrinogen and FAR remained independently associated with severe PE after adjustment for maternal age, body mass index, and gestational age at sampling. FAR did not demonstrate superior discriminatory performance compared with fibrinogen alone. PAR did not differ significantly among groups, while CrAR was higher in preeclampsia than in controls but did not discriminate severe disease. Conclusions: Fibrinogen and FAR were associated with severe PE but demonstrated only modest discriminatory performance. FAR did not outperform fibrinogen alone, and its incremental value beyond fibrinogen remains uncertain. Therefore, these findings should be considered exploratory and do not support the use of FAR or fibrinogen as standalone tools for clinical screening, risk stratification, or decision-making. Further prospective, multicenter studies are needed to determine whether these markers provide clinically meaningful value within broader multimodal assessment models.

PMID 42941226
阅读全文 →
PubMedJournal of clinical medicine2026-10-27

Association of Platelet-Albumin-Bilirubin and Albumin-Bilirubin Scores with Angiographic No-Reflow in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary PCI.

Özlek Bülent B, Tanık Veysel Ozan VO, Taş Alperen A, Tokatlı Sena S et al.

Background: The platelet-albumin-bilirubin (PALBI) and albumin-bilirubin (ALBI) scores integrate routinely available laboratory parameters with potential relevance to microvascular injury. We investigated their associations with angiographic no-reflow and incremental predictive value in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). Methods: This retrospective, single-center study included 1539 consecutive patients with STEMI undergoing primary PCI. No-reflow was defined by final TIMI flow < 3 and/or myocardial blush grade 0-1 in the absence of a mechanical cause. Associations of PALBI and ALBI with no-reflow were assessed using multivariable logistic regression. Discrimination, calibration, reclassification, internal bootstrap validation, and restricted cubic spline analyses were performed. Results: No-reflow occurred in 146 patients (9.5%). Both PALBI (adjusted odds ratio [aOR] per 0.1-point increase, 1.315; 95% confidence interval [CI], 1.228-1.408; p < 0.001) and ALBI (aOR, 1.165; 95% CI, 1.115-1.218; p < 0.001) were independently associated with no-reflow. PALBI showed greater discrimination than ALBI (AUC, 0.722 vs. 0.681; DeLong p = 0.018). Adding PALBI to the clinical model increased the AUC from 0.688 to 0.785 (ΔAUC = 0.098; p = 0.001), with significant NRI (0.777) and IDI (0.102), and improved the Brier score from 0.083 to 0.073. The optimism-corrected AUC was 0.762. PALBI demonstrated a non-linear association with no-reflow (p for non-linearity <0.001), whereas ALBI showed a predominantly linear association. Conclusions: Higher PALBI and ALBI scores were independently associated with angiographic no-reflow after primary PCI in STEMI. PALBI demonstrated stronger discrimination and incremental predictive performance; however, external validation and prospective evaluation are required to determine its potential clinical utility.

PMID 42941386
阅读全文 →
PubMedPolymers2026-10-27

Sustainable Approach to Thermoplastic Polyurethanes Stabilization: Vanillin as a Natural Additive in Melt-Processing.

Smorawska-Kliza Joanna J, Jażdżewska Anna A, Głowińska Ewa E

Thermo-oxidative degradation during high-temperature processing remains a major challenge limiting the performance of thermoplastic polyurethanes (TPUs). This study evaluated vanillin (4-hydroxy-3-methoxybenzaldehyde), a bio-based phenolic compound, as a primary thermo-oxidative stabilizer acting as a free-radical scavenger. Bio-based TPU (bio-TPU) was synthesized via a two-step method using a commercial bio-based polyol, a bio-based chain extender, and a mixture of diisocyanates. During processing in an internal mixer, vanillin was incorporated into both bio-TPU and a commercial TPU at concentrations of 0.03, 0.165, and 0.3 wt%. Changes in chemical structure were assessed by Fourier-transform infrared spectroscopy (FTIR), thermal properties were evaluated by thermogravimetric analysis (TGA) and differential scanning calorimetry (DSC), including oxidation onset temperature (OOT) measurements, and dynamic mechanical analysis (DMA). Mechanical properties were assessed by tensile test and hardness. FTIR analysis revealed no significant structural changes after vanillin addition. However, changes in thermal properties were observed, including an increase in the OOT for materials containing the highest vanillin content. TGA results also showed a generally improved thermal stability at higher vanillin concentrations, approaching reference-material values at the highest concentration in the commercial TPU. A slight decrease in mechanical properties was observed. These findings demonstrate a pronounced stabilizing effect of 0.3 wt% vanillin on both bio-TPU and commercial TPU, providing new insights into the potential reuse and further recycling of TPU materials stabilized with bio-based additives.

PMID 42942660
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多albumin